Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"AJU Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Stuart Therapeutics

    Menu

    Stuart Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Stuart Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease

              Details:

              ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye Disease.

              Lead Product(s): Vezocolmitide

              Therapeutic Area: Ophthalmology Product Name: ST-100

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ora, Inc

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stuart Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

              Details:

              Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.

              Lead Product(s): ST-113

              Therapeutic Area: Ophthalmology Product Name: ST-113

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Glaukos

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stuart Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.

              Details:

              ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.

              Lead Product(s): ST-100

              Therapeutic Area: Ophthalmology Product Name: ST-100

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: AJU Pharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY